Category

• Pipeline4

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• Glaucoma4
• Clinical Trials3
• Contact Lenses3
• Contact Lens2
• Glaucoma Medications2
• Lens Technology2
• IOP1
• Ocular Hypertension1
• Technology1

• Organizations: MediPrint Ophthalmics ✕

Clear all

Pipeline

MediPrint reports positive phase 2 data on 3D-printed, drug-eluting CL for glaucoma

LL-BMT1 achieved equivalence to the efficacy of bimatoprost 0.01% in IOP reduction as well as an 86% reduction in treatment frequency versus eye drops.

Pipeline

MediPrint Ophthalmics completes phase 2 study on drug-eluting contact lens

SIGHT-2 reports positive data for LL-BMT1 in treating glaucoma and ocular hypertension. 

Pipeline

MediPrint Ophthalmics releases data from SIGHT-2 phase 2 trial for glaucoma

The SIGHT program is assessing the safety and efficacy of LL-BMT1, a preservative-free, drug-eluting contact lens.

Pipeline

MediPrint Ophthalmics begins phase 2b study for drug-eluting lens

MediPrint Ophthalmics has officially commenced its phase 2b study of its drug-eluting contact lens for glaucoma and ocular hypertension: LL-BMT1.